Azelis announces distribution mandate for DFE Pharma’s excipient solutions to EMEA countries
31 October 2022
Azelis, a leading global innovation service provider in the specialty chemicals and food ingredients industry, has been appointed as a distributor by DFE Pharma, a global leader in high-quality functional excipients for pharmaceuticals and nutraceuticals. Effective immediately, Azelis’ customers in UK, Ireland, France, the Benelux (Belgium, Netherlands, Luxembourg), Turkey, Poland, the Nordics (Denmark, Norway, Sweden, Finland, Iceland) and DACH (Austria, Germany, and Switzerland) have access to a large part of DFE Pharma’s range of pharmaceutical excipients.
This new partnership allows Azelis to exclusively distribute the following DFE Pharma excipients: Nutracel®, Pharmacel® and Pharmacel® sMCC90, high quality MCCs and co-processed MCC (microcrystalline cellulose) used as filler and binder in oral dosage forms. The agreement also includes Primellose® (croscarmellose sodium), a super disintegrant used in oral dosage forms. DFE Pharma's excipients offer advantages such as high-cost efficiency, consistent high quality, and adaptability to meet the customer needs. This new mandate is in line with Azelis' overall strategy to grow organically and establish significant partnerships with leading performance chemical suppliers.
Matthew Dickman, Azelis Market Segment Director Pharma & Healthcare says:
“We are thrilled about this new partnership with DFE Pharma, a leading manufacturer in the MCC (Microcrystalline Cellulose) product group, the oldest but most widely used product of the pharmaceutical industry. Their high-quality product line perfectly completements both our pharmaceuticals and nutraceuticals portfolio.We can supply a greater variety of products to our customers, reinforcing our lateral value chain.”
Ulrich Deutschmann, Chief Commercial Officer at DFE Pharma, adds:
“Working with Azelis was a key strategic decision, as their pharmaceuticals market coverage and knowledge, technical expertise, and established presence in the industry make them a valuable growth partner for us. We are excited to offer highly competitive products to the market, such as Primellose®for oral dosage forms, as well as our MCC portfolio, which has been tested to have very low nitrites, nitrates, and nitrosamines levels, addressing a major concern for pharmaceutical and nutraceutical companies. We look forward to further developing our business with Azelis in selected EMEA countries.”